

UK-383367

## Chemical Properties

CAS No. : 348622-88-8


Formula: C15H24N4O4

Molecular Weight: 324.38

Storage: Keep away from direct sunlight, Store at low temperature

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

|               |   |
|---------------|---|
| Description   | UK-383367 is a procollagen C-proteinase inhibitor with IC50 of 44 nM, has excellent selectivity over MMPs.  |
| Targets(IC50) | Procollagen C Proteinase  |
| In vitro      | UK-383367 is effective at penetrating human skin. [1] UK-383367 inhibits collagen deposition with IC50 of ~2 μM. UK-383367 has modest affinity for all the PDE-4 subtypes PDE-4a, PDE-4b, PDE-4c and PDE-4d with IC50 of 1.8 μM, 1.5 μM, 2.4 μM and 0.9 μM, respectively. [2] UK-383367 is a weakly acidic compound and lipophilic. [3]   |
| In vivo       | Plasma protein binding values for UK-383367 in rat, dog and human are 95%, 93% and 94%, respectively. UK-383367 following incubation in rat plasma results in the half-life of 49?min. UK-383367 following single intravenous administration (2 mg/kg) to rat results in the plasma clearance of 157?mL min <sup>-1</sup> ?kg <sup>-1</sup> , the volume of distribution of 12?L kg <sup>-1</sup> , and an elimination half-life of 0.8? hour. UK-383367 following single intravenous administration (0.5 mg/kg) to dog results in the plasma clearance of 35?mL min <sup>-1</sup> ?kg <sup>-1</sup> , the volume of distribution of 4.6?L kg <sup>-1</sup> , and an elimination half-life of 1.5?hours. UK-383367 following oral administration (2 mg/kg) to dog results in Cmax of 110 ng/mL, Tmax of 0.5-1.5 hour and oral bioavailability of 13%. [3] |

## Solubility Information

|                     |   |
|---------------------|---|
| Solubility          | Ethanol: 65 mg/mL (200.38 mM), Sonication is recommended.<br>DMSO: 65 mg/mL (200.38 mM), Sonication is recommended.<br>H2O: < 1 mg/mL (insoluble or slightly soluble),<br>(< 1 mg/ml refers to the product slightly soluble or insoluble)   |
| In vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.17 mM), Sonication is recommended.<br><i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i> |

### Preparing Stock Solutions

---

|       | <b>1mg</b> | <b>5mg</b> | <b>10mg</b> |
|-------|------------|------------|-------------|
| 1 mM  | 3.0828 mL  | 15.414 mL  | 30.828 mL   |
| 5 mM  | 0.6166 mL  | 3.0828 mL  | 6.1656 mL   |
| 10 mM | 0.3083 mL  | 1.5414 mL  | 3.0828 mL   |
| 50 mM | 0.0617 mL  | 0.3083 mL  | 0.6166 mL   |

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Fish PV, et al. J Med Chem, 2007, 50(15), 3442-3456.

Bailey S, et al. Bioorg Med Chem Lett, 2008, 18(24), 6562-6567.

Allan GA, et al. Xenobiotica, 2006, 36(5), 399-418.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481